TARDBP and amyotrophic lateral sclerosis: We consider that this approach should be replicated with more extensive methods and other primary antibodies (anti-CTD, anti-pTDP-43) before rejecting muscle biopsy as a TDP-43-based in vivo biomarker for ALS.